Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Neurosurgery

• Publication date

  2009-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3171/2008.7.JNS08143PMID 19199506
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors

  2008cited by this paper
• Brain metastases in breast cancer: prognostic factors and management

  2008cited by this paper
• Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

  2007cited by this paper
• Reversible posterior leukoencephalopathy syndrome induced by sunitinib.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer

  2007cited by this paper
• Influence of breast cancer resistance protein (Abcg2) and p‐glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood–brain barrier

  2007cited by this paper
• Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

  2007cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.

  2006cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• Clinical Study of Brain Metastasis of Renal Cell Carcinoma

  1999cited by this paper

• Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis

  2023cites this paper
• Neurologic Complications of Corticosteroids in Cancer Therapy

  2018cites this paper
• ACR–ASNR–SPR PRACTICE PARAMETER FOR THE PERFORMANCE OF MAGNETIC RESONANCE IMAGING (MRI) OF THE PEDIATRIC SPINE

  2017cites this paper
• Isolated clival metastasis: a rare presentation of renal cell carcinoma

  2017cites this paper
• Metastatic Renal Cell Carcinoma Mimicking Trigeminal Schwannoma in a Patient Presenting with Trigeminal Neuralgia

  2015cites this paper
• Psychotic disorder induced by a combination of sorafenib and BAY86-9766.

  2014cites this paper
• Treatment of Brain Metastases: Chemotherapy

  2012cites this paper
• Antiangiogéniques et métastases cérébrales: plus de peur que de mal ?

  2012cites this paper
• Therapie von Hirnmetastasen und Meningeosis neoplastica

  2011cites this paper
• Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases.

  2011cites this paper
• Imaging Biomarkers of Response to Radiation and Anti-angiogenic Agents in Brain Tumors

  2011influential citation
• Breast Cancer and Renal Cell Cancer Metastases to the Brain

  2011cites this paper
• Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases

  2011cites this paper
• Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice.

  2010cites this paper
• Targeted therapies in renal cell cancer: recent developments in imaging

  2010cites this paper
• Sorafenib plus valproic acid for infant spinal glioblastoma.

  2010cites this paper
• Antiangiogenic strategies in breast cancer management.

  2010cites this paper
• Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.

  2010cites this paper
• Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

  2009cites this paper